SBSD Stock Overview
Designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Stratec SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €32.60 |
| 52 Week High | €39.10 |
| 52 Week Low | €32.60 |
| Beta | 0.23 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -75.23% |
| 5 Year Change | -50.83% |
| Change since IPO | -38.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| SBSD | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 2.2% |
| 1Y | n/a | -2.4% | 8.8% |
Return vs Industry: Insufficient data to determine how SBSD performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how SBSD performed against the UK Market.
Price Volatility
| SBSD volatility | |
|---|---|
| SBSD Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: SBSD's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine SBSD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 1,462 | Marcus Wolfinger | www.stratec.com |
Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers; and offers complex consumables for diagnostics and medical applications. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018.
Stratec SE Fundamentals Summary
| SBSD fundamental statistics | |
|---|---|
| Market cap | €334.90m |
| Earnings (TTM) | €10.01m |
| Revenue (TTM) | €250.54m |
33.4x
P/E Ratio1.3x
P/S RatioIs SBSD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBSD income statement (TTM) | |
|---|---|
| Revenue | €250.54m |
| Cost of Revenue | €182.78m |
| Gross Profit | €67.75m |
| Other Expenses | €57.74m |
| Earnings | €10.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.82 |
| Gross Margin | 27.04% |
| Net Profit Margin | 4.00% |
| Debt/Equity Ratio | 67.0% |
How did SBSD perform over the long term?
See historical performance and comparison